C11-Acetate PET/CT in Multiple Myeloma: Added Value to F18-Fluorodeoxyglucose PET/CT (ACTMM)

Chang Gung Medical Foundation

Status: Completed

Conditions: Multiple Myeloma

Treatments: Other: ACT PET/CT

Study type: Interventional

Funder types: Other

Identifiers

NCT01691300

99-2177A

Details and patient eligibility

About

Positron emission tomography combined with computed tomography using carbon-11 acetate (ACT PET/CT) may help detect lesions before treatment and evaluate response following therapy in patients with from multiple myeloma (MM). This study aimed to prospectively assess the clinical utility of ACT PET/CT in MM as compared to the commonly used F18-fluorodeoxyglucose(FDG).

Enrollment: 30 patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• at least 20 years of age
• previously untreated
• complete pre-treatment clinical staging including bone marrow examination
• written informed consent to participate in the study

Exclusion criteria

• concurrent active malignant tumor(s)
• pregnant or breast feeding women
• non-compliant to PET/CT or to MRI
• marked renal impairment (contraindicated for contrast-enhanced MRI)

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

30 participants in 1 patient group

ACT PET/CT

Experimental group

Description:

Dual-tracer ACT/FDG PET/CT and WB-DCE-MRI at baseline (pretreatment), post-induction and post-ASCT (if eligible)

Treatment:

Other: ACT PET/CT